Abstract: The current invention reports a method for concentrating an immunoglobulin solution by tangential flow filtration wherein the transmembrane pressure and the cross-flow are variable.
Type:
Grant
Filed:
July 15, 2008
Date of Patent:
January 21, 2014
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Stefan Hepbildikler, Wolfgang Kuhne, Eva Rosenberg, Gerhard Winter
Abstract: A process for producing polyamides from the corresponding monomers and/or prepolymers comprises the steps of (a) reacting the monomers and/or prepolymers and optionally further components under polyamide-forming reaction conditions to form polyamide, (b) treating the polyamide obtained in step (a) in a kneader above the melting temperature of the polyamide, (c) further processing the polyamide from step (b) into pellet, film, fiber or moldings, preferably pelletizing the polyamide, (d) extracting some or all unconverted monomers and any product dimers and oligomers and also optionally further components from the polyamide and/or drying the polyamide.
Abstract: The present invention relates to a method for the production of a hepatitis B antigen suitable for use in a vaccine, the method comprising purification of the antigen in the presence of cysteine, to vaccines comprising such antigens.
Type:
Grant
Filed:
December 23, 2008
Date of Patent:
January 7, 2014
Assignee:
Glaxosmithkline Biologicals, S.A.
Inventors:
Koen De-Heyder, Peter Schu, Michelle Serantoni, Omer Van-Opstal
Abstract: The invention includes methods of isolating a multi-subunit protein which binds to an antigen-bearing moiety. The methods comprise generating a phage display library comprising a plurality of virus vectors.
Type:
Grant
Filed:
March 26, 2010
Date of Patent:
January 7, 2014
Assignee:
The Trustees of the University of Pennsylvania
Abstract: A method for protein refolding with an ion exchange resin. The method includes (a) choosing an ion exchange resin that having charged groups with the same sign as a net charge of a denatured protein to be refolded; (b) removing heterogeneous ions from the ion exchange resin by washing the ion exchange resin sequentially with saline solution and deionized water, to prepare the ion exchange resin; (c) mixing the ion exchange resin with a refolding buffer thoroughly, then adding the denatured protein to the refolding buffer and allowing the denatured protein to refold; and then (d) collecting the supernatant by centrifugation or settlement, to obtain a solution containing the refolded protein.
Type:
Grant
Filed:
June 30, 2011
Date of Patent:
January 7, 2014
Assignee:
Tianjin University
Inventors:
Yan Sun, Guozhen Wang, Qinghong Shi, Xiaoyan Dong
Abstract: The present invention relates to recombinant mussel adhesive protein wherein a DOPA residue is in vivo incorporated instead of a tyrosine residue, and a method for producing the same. More specifically, the present invention relates to recombinant mussel adhesive protein wherein a DOPA residue is incorporated instead of a tyrosine residue, and a method for producing the same, and a transformant for producing the recombinant mussel adhesive protein.
Abstract: The invention provides an isolated major ampullate spidroin protein, which consists of from 150 to 420 amino acid residues and is defined by the formula REP-CT. REP is a repetitive, N-terminally derived protein fragment having from 80 to 300 amino acid residues. CT is a C-terminally derived protein fragment having from 70 to 120 amino acid residues. The invention further provides an isolated fusion protein consisting of a first protein fragment, which is a major ampullate spidroin protein, and a second protein fragment comprising a fusion partner and a cleavage agent recognition site. The first protein fragment is coupled via said cleavage agent recognition site to the fusion partner. The invention also provides a method of producing a major ampullate spidroin protein and polymers thereof.
Type:
Grant
Filed:
August 29, 2012
Date of Patent:
December 31, 2013
Assignee:
Spiber Technologies AB
Inventors:
Jan Johansson, Göran Hjäm, Margareta Stark, Anna Rising, Stefan Grip, Wilhelm Engström, My Hedhammar
Abstract: The present invention provides the method of obtaining IgA and IgM antibodies from chicken egg whites. The method involves separating chicken egg whites into two fractions which contain IgA and IgM antibodies exclusively. This separation method consists of raising the volume of the egg whites using purified water, lowering the pH of said volume, filtering the IgM fraction from said volume, precipitating the IgA fraction from the remaining volume, dialyzing the IgA fraction and drying the IgA and IgM fractions.
Abstract: Provided is a peptide containing a variable region and improved in production efficiency. The peptide contains a variable region to which an antigen-binding site is to be formed and has an amino acid sequence expressing a specific adsorption function to a solid phase at a site closer to the C-terminal than a heavy-chain variable region or at a site closer to the C-terminal than a light-chain variable region.
Type:
Grant
Filed:
February 12, 2009
Date of Patent:
December 31, 2013
Assignees:
Enplas Corporation, National University Corporation Kyoto Institute of Technology
Abstract: A naturally occurring or recombinant urate oxidase (uricase) covalently coupled to poly(ethylene glycol) or poly(ethylene oxide) (both referred to as PEG), wherein an average of 2 to 10 strands of PEG are conjugated to each uricase subunit and the PEG has an average molecular weight between about 5 kDa and 100 kDa. The resulting PEG-uricase conjugates are substantially non-immunogenic and retain at least 75% of the uricolytic activity of the unmodified enzyme.
Type:
Grant
Filed:
April 8, 2011
Date of Patent:
December 31, 2013
Assignees:
Mountain View Pharmaceuticals, Inc., Duke University
Inventors:
L. David Williams, Michael S. Hershfield, Susan J. Kelly, Mark G. P. Saifer, Merry R. Sherman
Abstract: Embodiments of the present invention generally relate to processing of peptides in urea solutions and substantial prevention of carbamylation of the peptide.
Type:
Application
Filed:
August 20, 2013
Publication date:
December 19, 2013
Applicant:
Fujifilm Diosynth Biotechnologies U.S.A., Inc.
Inventors:
Philip A. Ropp, Christie Lynn Williams, Michael Murray, Miao Fang Lin
Abstract: The invention disclosed is a method of purifying Diphtheria Toxoid (DT) by Hydrophobic Interaction Chromatography (HIC). The chromatographic method of the present invention provides an effective removal of contaminating glycans present in carrier protein DT and thereby provides a highly purified form of carrier protein DT for the production or preparation of polysaccharide protein conjugate vaccines.
Abstract: Embodiments of the present invention provide processes for preparing thymus extracts and plant or fungal extracts, and more particularly provide compositions (Thyex-1-6A and -6B) produced in accordance with said processes, and methods for treatment of various conditions comprising administration of said compositions including but not limited to impaired physical vigor or aptitude, and aging and/or age-related conditions (arthritis, mobility deficits, loss of appetite, etc.). Additional aspects provide methods for building muscle mass, for reducing exercise recovery period, or for sustaining exercise intensity. Particular aspects relate to preparation of Houttuynia cordata extracts and the use of those extracts as an anti-emetic and/or anti-nausea treatment for a subject in need thereof.
Abstract: The invention relates to a method for purifying a glycoprotein, preferably FSH or a FSH mutant, comprising the steps of subjecting a liquid containing FSH or a FSH mutant to: (1) a dye affinity chromatography; (2) a weak anion exchange chromatography; (3) a hydrophobic interaction chromatography; and (4) a strong anion exchange chromatography; which may be carried out in any order.
Type:
Grant
Filed:
December 6, 2006
Date of Patent:
December 10, 2013
Assignee:
Ares Trading S.A.
Inventors:
Thierry Ziegler, Mara Rossi, Antonello Datola, Sabrina Fiumi
Abstract: The invention relates to a novel process for isolating milk proteins from milk or from whey; its subject is also a milk protein fraction obtained by this process and its use for the preparation of pharmaceutical or food compositions.
Abstract: The invention provides amphiphilic compounds and methods for manipulating membrane proteins. Compounds of the invention, for example, the compounds of Formulas I-XIX, can be prepared from readily available starting materials. The amphiphilic compounds can manipulate membrane protein at relatively low concentrations compared to many known detergents. The compounds can be used to aid the isolation of membrane proteins, for example, to aid their solubilization and/or purification. The compounds can also be used to aid the functional and structural determination of membrane proteins, including their stabilization and crystallization.
Type:
Application
Filed:
August 7, 2013
Publication date:
December 5, 2013
Applicants:
The Board of Trustees of the Leland Stanford Junior University, Wisconsin Alumni Research Foundation
Inventors:
Samuel Helmer GELLMAN, Pil Seok CHAE, Brian KOBILKA, Soren RASUMSSEN
Abstract: The invention is related to a process for separating proteins fibrinogen, Factor XIII and biological glue from a solubilized plasma fraction and for preparing freeze-dried concentrates of said proteins comprising the steps of: chromatographic purification comprising the steps of loading an anion exchanger of weak base type with the said solubilized fraction, previously equilibrated with a buffer of a predetermined ionic strength of an alkaline pH, which allows to retain the biological glue, elution of the biological glue by increasing the ionic strength of the said buffer, and separation of FXIII from fibrinogen by addition to at least one part of the biological glue eluate of at least one chemical agent precipitating the FXIII, and recovery of the resulting purified fibrinogen containing supernatant solution, and diafiltration of the fibrinogen, biological glue and resolubilized FXIII solutions, followed by a freeze-drying of said solutions.
Type:
Grant
Filed:
June 28, 2006
Date of Patent:
December 3, 2013
Assignee:
Laboratoire Francais du Fractionnement et des Biotechnologies
Inventors:
Nogré Michel, Porte Pierre, Tellier Michel
Abstract: There is described a coated solid phase microextraction (SPME) fiber for use in direct immersion SPME of a food matrix that includes carbohydrates. The coated SPME fiber includes a SPME fiber for absorbing a small molecule from the food matrix; and a protective coating which has a surface that is substantially uniform and substantially smooth, the protective coating reducing adsorption of the carbohydrates onto the SPME fiber and allowing the SPME fiber to extract the small molecule from the food matrix. A process for producing the coated SPME fiber and a method of performing solid phase microextraction are also described.
Abstract: The present invention relates to a process for producing immunogenic polypeptides, comprising reducing disulfide bonds and blocking the resulting free thiol group with a blocking agent. The immunogenic peptides comprise a fragment of MAGE A3.
Abstract: The present invention relates to modified immunoglobulin-binding proteins, e.g., Staphylococcus protein A, having improved binding specificity for immunoglobulins and methods of making and using the same.
Abstract: A high-purity fragment is obtained by a simple mechanism and method for separating and purifying a nucleic acid, particularly fragment DNA, extremely efficiently and with a high reproducibility, wherein elution with a high-concentration salt is not performed and necessity of elution and purification is eliminated. This mechanism is a mechanism for purifying a nucleic acid, particularly fragment DNA using a monolith structure formed with glass or silica, specifically, an integral porous body having an open structure with pores that communicate the upper end with the lower end, wherein through-pores corresponding to nucleic acid sizes of 35 bp (mer) to 100 Kbp (mer) are provided.
Abstract: The invention relates, in part, to monovalent streptavidin compositions. The invention also relates to methods of preparing and using monovalent streptavidin compositions. In some aspects of the invention, the compositions are monovalent streptavidin with a single femtomolar biotin-binding site.
Abstract: Ligand functionalized substrates, methods of making ligand functionalized substrates, and methods of using functionalized substrates are disclosed.
Type:
Grant
Filed:
May 27, 2009
Date of Patent:
November 19, 2013
Assignees:
3M Innovative Properties Company, Wisconsin Alumni Research Foundation
Inventors:
Mark R. Etzel, Yi He, Steven M. Heilmann, Jerald K. Rasmussen, Kannan Seshadri, Simon K. Shannon, Clinton P. Waller, Jr., Douglas E. Weiss
Abstract: The present invention provides an absorbent which can remove cells present in blood including activated leukocytes such as granulocytes and monocytes, and cancer cells as well as can remove cytokines which facilitate the activation of the remaining cells, and further has no concern for pressure loss and has high configuration stability. That is, the present invention provides an absorbent which absorbs the granulocytes and the monocytes in blood, an absorbent for cancer therapy which absorbs an immunosuppressive protein and an absorbent having a bilayer structure of a net and a nonwoven fabric, having a zeta potential of ?20 mV or more, as well as a blood circulation column containing any of the absorbents filled therein.
Abstract: The subject invention provides silica-based material that has high affinity to chitin, chitin derivatives and chitin-containing microorganisms at an acidic pH. In an embodiment, the silica-based material surface comprises glass. Also provided are methods for preparing the subject silica-based chitin-binding material. In addition, the subject invention provides rapid, specific, sensitive, accurate and convenient methods for detection, isolation and purification of chitin, chitin derivatives and chitin-containing microorganisms.
Abstract: The current invention reports a method for concentrating an immunoglobulin solution by tangential flow filtration wherein the transmembrane pressure and the cross-flow are variable.
Type:
Grant
Filed:
July 15, 2008
Date of Patent:
November 12, 2013
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Stefan Hepbildikler, Wolfgang Kuhne, Eva Rosenberg, Gerhard Winter
Abstract: The invention relates to methods for the isolation of AAT from solutions containing albumin and AAT using at least two separate metal chelate chromatography steps. The product may be further purified and/or subjected to one or more virus inactivation or reduction steps. The isolated AAT may then be formulated for pharmaceutical use.
Type:
Grant
Filed:
November 29, 2006
Date of Patent:
November 12, 2013
Assignee:
Bio Products Laboratory Limited
Inventors:
Peter Kumpalume, Adrian Podmore, Joan Dalton
Abstract: The present invention pertains to crystals of glucokinase regulatory protein (GKRP) and of GKRP variants, to the molecular biology of certain GKRP variants, to processes for the crystallization of GKRP and GKRP variants, to such crystals and corresponding structural information obtained by X-ray crystallography. Such crystals and crystallographic data can be used for the identification of compounds that bind to GKRP, especially of compounds that inhibit GKRP or interfere with the interaction of GKRP with its natural interacting partner Glucokinase (GK).
Type:
Application
Filed:
December 17, 2012
Publication date:
November 7, 2013
Applicant:
Boehringer Ingelheim International GmbH
Inventors:
Gisela SCHNAPP, Adina Berg, Stefan Kauschke, Martin Lenter, Alexander Pautsch, Wolfgang Rist
Abstract: The present invention relates to a selectively soluble polymer capable of binding to a desired molecules in an unclarified mixture containing various biological materials and the methods of using such a polymer to purify a molecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and/or salt concentration and is rendered insoluble and precipitates out of solution upon a change in the process conditions. The polymer is capable of binding to the desired molecule (protein, polypeptide, etc) and remains capable of binding to that molecule even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered such as by elution and further processed.
Abstract: Capture compounds and collections thereof and methods using the compounds for the analysis of biomolecules are provided. In particular, collections, compounds and methods are provided for analyzing complex protein mixtures, such as the proteome. The compounds are multifunctional reagents that provide for the separation and isolation of complex protein mixtures. Each compound has the formula: wherein: Z is a trityl derivative; X, the reactivity function, covalently binds to amino acid side chains of proteins; Y, the selectivity function, modulates binding of X to the amino acid side chains in proteins such that X binds to fewer proteins when Y is present than in its absence; and Q permits separation or immobilization of the capture compound. Automated systems for performing the methods also are provided.
Type:
Grant
Filed:
November 2, 2010
Date of Patent:
October 29, 2013
Assignee:
Pharmaceuticals, Inc.
Inventors:
Hubert Köster, Suhaib Siddigi, Daniel P. Little
Abstract: The present disclosure relates to a method for reducing nuclease activity in a subtilisin solution obtained from a fermentation broth including: a) adjusting the pH of the subtilisin solution to a pH in the range of from pH 8.5 to pH 10.5; b) adding a polyol; and c) adjusting the temperature of the subtilisin solution to a temperature in the range of from 50° C. to 80° C. In accordance with the present disclosure, the nuclease activity is reduced to less than 5% of the initial value and the subtilisin activity is maintained at more than 60% of the initial value.
Type:
Grant
Filed:
August 19, 2008
Date of Patent:
October 15, 2013
Assignee:
Novozymes A/S
Inventors:
Kim Uhre Hansen, Peter Rahbek Oestergaard
Abstract: Methods for selective extraction and fractionation of algal proteins from an algal biomass or algal culture are disclosed. A method of selective removal of products from an algal biomass provides for single and multistep extraction processes which allow for efficient separation of algal proteins. These proteins can be used as renewable sources of proteins for animal feedstocks and human food. Further, lipids remaining in the algal biomass after extraction of proteins can be used to generate renewable fuels.
Abstract: The present invention relates to a new and improved method for preparing a highly concentrated immunoglobulin composition from pooled plasma for subcutaneous injection. A composition comprising 20% or more immunoglobulin suitable for subcutaneous use is also described.
Type:
Grant
Filed:
May 27, 2010
Date of Patent:
October 1, 2013
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Inventors:
Wolfgang Teschner, Harald Arno Butterweck, Azra Pljevljakovic, Theresa Friederike Bauer, Bernhard Koelbl, Hans-Peter Schwarz, Nebojsa Nikolic, Gerhard Poelsler, Johanna Kindermann
Abstract: It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure.
Type:
Grant
Filed:
September 23, 2011
Date of Patent:
September 17, 2013
Assignee:
Dyax Corp.
Inventors:
Jinan Yu, M. Daniel Potter, Brian D. Kelley, Jeffrey S. Deetz, James E. Booth
Abstract: The present invention pertains to a process for production of recombinant arylsulfatase A in a cell culture system, the process comprising culturing a mammalian cell capable of producing rASA in liquid medium in a system comprising one or more bio-reactors; and concentrating, purifying and formulating the rASA by a purification process comprising one or more steps of chromatography. Other aspects of the invention provides a pharmaceutical composition comprising rASA, which is efficiently endocytosed via the mannose-6-phosphate receptor pathway in vivo as well as a rhASA a medicament and use of a rhASA for the manufacture of a medicament for reducing the galactosyl sulphatide levels within target cells in the peripheral nervous system and/or within the central nervous system in a subject.
Abstract: A method for reducing or substantially preventing formation of a trisulfide derivative of a polypeptide in a liquid medium containing the polypeptide ijn question comprises stripping the liquid medium with a gas, suitably a chemically unreactive gas such as nitrogen or argon.
Abstract: The invention relates provides a novel crystal structure of the fibrillogenic part of amyloid ?-peptide (A?). More specifically the crystal structure is A?-IgNAR and, accordingly the present invention also relates to selecting and/or designing compounds that modulate amyloid ?-peptide (A?) activity using techniques such as in silico screening and crystal soaking experiments. The invention further relates to compounds and methods for inhibiting interaction between amyloid ?-peptide (A?) monomers, more particularly, inhibiting or disrupting amyloid ?-peptide (A?) oligomer formation and toxic activity.
Type:
Grant
Filed:
October 6, 2009
Date of Patent:
September 3, 2013
Assignee:
Commonwealth Scientific and Industrial Research Organisation
Inventors:
Stewart Douglas Nuttall, Victor Anatolievich Streltsov, Joseph Noozhumurry Varghese, Vidanagamage Chandana Epa
Abstract: The current invention comprises a method for producing an immunoglobulin or immunoglobulin fragment with defined glycostructure comprising the following steps: a) providing an affinity chromatography column eluate containing the immunoglobulin or immunoglobulin fragment, b) incubating the affinity chromatography column eluate with (?1,3)galactosidase of plant origin, e.g. from green coffee beans (EC 3.2.1.22), c) applying the incubated affinity chromatography column eluate to a protein A chromatography material and recovering the immunoglobulin or immunoglobulin fragment from the protein A chromatography material and thereby producing an immunoglobulin or immunoglobulin fragment with defined glycostructure.
Type:
Grant
Filed:
July 28, 2010
Date of Patent:
September 3, 2013
Assignee:
Hoffman-La Roche, Inc.
Inventors:
Markus Haberger, Christine Jung, Dietmar Reusch
Abstract: The method of the present invention comprising successive column chromatography processes for the purification of an anthrax protective antigen can achieve an improved purity of the anthrax protective antigen product by effectively removing impurities (e.g., cellular residual proteins in the culture solution) without the loss of anthrax protective antigen. Therefore, the method of the present invention can be advantageously used for economically producing the anthrax protective antigen on a large scale.
Type:
Grant
Filed:
January 9, 2009
Date of Patent:
August 27, 2013
Assignees:
Korea Center For Disease Control and Prevention, Green Cross Corporation
Inventors:
Hee-Bok Oh, Bong-Su Kim, Gi-Eun Rhie, Jeong-Hoon Chun, Hun Kim, SinKoo Yeo, MahnHoon Park, Chong-Hwan Jonathan Chang, Mi Sun Ahn
Abstract: The invention relates to a process for reducing the concentration of free Fc-moieties in a fluid comprising an Fc-containing protein comprising a cation exchange chromatography step.
Abstract: A soy protein product having a protein content of at least about 60 wt % (N×6.25) d.b., preferably an isolate, is formed by a procedure in which soy protein is extracted from a soy source material using an aqueous calcium chloride solution at low pH, generally about 1.5 to about 5, and separating the resulting aqueous soy protein solution from residual soy protein source. The resulting clarified aqueous soy protein solution may be diluted and the pH adjusted within the range of 1.5-5.0. The solution may be concentrated by ultrafiltration, diafiltered and then dried to provide the soy protein product. The soy protein product is soluble in acidic medium and produces transparent, heat stable solutions and hence may be used for protein fortification of soft drinks and sports drinks.
Type:
Grant
Filed:
June 30, 2010
Date of Patent:
August 6, 2013
Assignee:
Burcon Nutrascience (MB) Corp.
Inventors:
Kevin I. Segall, Martin Schweizer, Brent E. Green, Sarah Medina, Brandy Gosnell
Abstract: The present invention relates to methods for the manufacture, purification, formulation, and use of biologically active recombinant elastase proteins. Described are recombinant methods for producing therapeutically useful elastase proteins, as are pharmaceutical compositions comprising said elastase proteins. Novel recombinant elastase proteins and protein preparations are also disclosed. Methods are described for treating and preventing diseases of biological conduits using pharmaceutical compositions containing the elastase proteins of the invention.
Type:
Grant
Filed:
December 3, 2008
Date of Patent:
August 6, 2013
Assignee:
Proteon Therapeutics, Inc.
Inventors:
F. Nicholas Franano, Kimberly S. Bland, Marco D. Wong, Bee C. Ding
Abstract: Provided is a purification method that purifies an antibody to a high purity, effectively removes antibody polymer (or aggregate), and improves antibody recovery rate. An antibody purification method including a step for treating a solution containing an antibody by mixed mode chromatography in the presence of an amino acid is provided.
Abstract: Methods, systems, and compositions related to generating and using a solution rich in interleukin-1 receptor antagonist are provided. Methods include contacting a liquid comprising white blood cells with a solid extraction material and stimulating with an electromagnetic field to activate production of interleukin-1 receptor antagonist. The interleukin-1 receptor antagonist can be separated from the solid extraction material. Methods for treating a site of inflammation in a patient include administering the solution rich in interleukin-1 receptor antagonist to the site of inflammation.
Abstract: A method of extracting a polypeptide from a biological sample includes contacting the biological sample with an extraction reagent to form a solution of the biological sample and the extraction reagent. The extraction reagent includes perfluorooctanoic and can be used at a concentration effective to solubilize the polypeptides in the biological sample.
Abstract: The invention includes a process for extracting a target protein from E. coli cells that includes lowering the pH of a whole E. coli cell solution to form an acidic solution, disrupting the cells to release the protein into the acidic solution, and separating the cellular debris from the released protein to obtain a protein product enriched in the heterologous target protein. The invention also includes addition of a solubility enhancer.